| Published Application/Species/Sample/Dilution | Reference |
|---|
- western blot knockout validation; human; 1:1000; loading ...; fig 6a
- immunocytochemistry; human; 1:400; loading ...; fig 5b, 8
| Zhang S, Eitan E, Wu T, Mattson M. Intercellular transfer of pathogenic α-synuclein by extracellular vesicles is induced by the lipid peroxidation product 4-hydroxynonenal. Neurobiol Aging. 2018;61:52-65 pubmed publisher |
- western blot; human; loading ...; fig 5c
| Cai M, Chai S, Xiong T, Wei J, Mao W, Zhu Y, et al. Aberrant Expression of Circulating MicroRNA Leads to the Dysregulation of Alpha-Synuclein and Other Pathogenic Genes in Parkinson's Disease. Front Cell Dev Biol. 2021;9:695007 pubmed publisher |
- western blot; mouse; 1:1000; loading ...; fig 5a, 5b, 5c, 5d
| Anandhan A, Nguyen N, Syal A, Dreher L, Dodson M, Zhang D, et al. NRF2 Loss Accentuates Parkinsonian Pathology and Behavioral Dysfunction in Human α-Synuclein Overexpressing Mice. Aging Dis. 2021;12:964-982 pubmed publisher |
- immunohistochemistry; human; 1:1000; loading ...; fig s2a
| Bengoa Vergniory N, Faggiani E, Ramos Gonzalez P, Kirkiz E, Connor Robson N, Brown L, et al. CLR01 protects dopaminergic neurons in vitro and in mouse models of Parkinson's disease. Nat Commun. 2020;11:4885 pubmed publisher |
- other; mouse; 1:500; loading ...; fig 4
| Cupo R, Shorter J. Skd3 (human ClpB) is a potent mitochondrial protein disaggregase that is inactivated by 3-methylglutaconic aciduria-linked mutations. elife. 2020;9: pubmed publisher |
- western blot; human; 1:1000; fig 1b
| de Oliveira G, Marques M, Cruzeiro Silva C, Cordeiro Y, Schuabb C, Moraes A, et al. Structural basis for the dissociation of ?-synuclein fibrils triggered by pressure perturbation of the hydrophobic core. Sci Rep. 2016;6:37990 pubmed publisher |
- western blot; human; fig 3
| Kang W, Chen W, Yang Q, Zhang L, Zhang L, Wang X, et al. Salivary total α-synuclein, oligomeric α-synuclein and SNCA variants in Parkinson's disease patients. Sci Rep. 2016;6:28143 pubmed publisher |
- western blot; human; fig 2
| Caviness J, Lue L, Hentz J, Schmitz C, Adler C, Shill H, et al. Cortical phosphorylated α-Synuclein levels correlate with brain wave spectra in Parkinson's disease. Mov Disord. 2016;31:1012-9 pubmed publisher |
- immunohistochemistry; mouse; fig 1
| Kim C, Ojo Amaize E, Spencer B, Rockenstein E, Mante M, Desplats P, et al. Hypoestoxide reduces neuroinflammation and α-synuclein accumulation in a mouse model of Parkinson's disease. J Neuroinflammation. 2015;12:236 pubmed publisher |
- western blot; human; fig 4
| Spencer B, Valera E, Rockenstein E, Trejo Morales M, Adame A, Masliah E. A brain-targeted, modified neurosin (kallikrein-6) reduces α-synuclein accumulation in a mouse model of multiple system atrophy. Mol Neurodegener. 2015;10:48 pubmed publisher |
- immunohistochemistry; human; 1:1000; fig 1
| Bourdenx M, Dovero S, Engeln M, Bido S, Bastide M, Dutheil N, et al. Lack of additive role of ageing in nigrostriatal neurodegeneration triggered by α-synuclein overexpression. Acta Neuropathol Commun. 2015;3:46 pubmed publisher |
| Wang X, Kang W, Yang Q, Zhang L, Chen S, Liu J. Using gastrocnemius sEMG and plasma ?-synuclein for the prediction of freezing of gait in Parkinson's disease patients. PLoS ONE. 2014;9:e89353 pubmed publisher |
- immunohistochemistry - free floating section; rat; 1:1000
| Reyes J, Rey N, Bousset L, Melki R, Brundin P, Angot E. Alpha-synuclein transfers from neurons to oligodendrocytes. Glia. 2014;62:387-98 pubmed publisher |
- immunohistochemistry - free floating section; human; 1:2000; fig 2
| Gombash S, Manfredsson F, Kemp C, Kuhn N, Fleming S, Egan A, et al. Morphological and behavioral impact of AAV2/5-mediated overexpression of human wildtype alpha-synuclein in the rat nigrostriatal system. PLoS ONE. 2013;8:e81426 pubmed publisher |
| Rieker C, Dev K, Lehnhoff K, Barbieri S, Ksiazek I, Kauffmann S, et al. Neuropathology in mice expressing mouse alpha-synuclein. PLoS ONE. 2011;6:e24834 pubmed publisher |
| A A, W C, N N, L M, M D, Zhang D. α-Syn overexpression, NRF2 suppression, and enhanced ferroptosis create a vicious cycle of neuronal loss in Parkinson's disease. Free Radic Biol Med. 2022;192:130-140 pubmed publisher |
| Liu X, Balaraman K, Lynch C, Hebron M, Shah P, Hu S, et al. Inhibition of Ubiquitin-Specific Protease-13 Improves Behavioral Performance in Alpha-Synuclein Expressing Mice. Int J Mol Sci. 2022;23: pubmed publisher |
| Medina C, Vargas E, Munger S, Miller J. Vocal changes in a zebra finch model of Parkinson's disease characterized by alpha-synuclein overexpression in the song-dedicated anterior forebrain pathway. PLoS ONE. 2022;17:e0265604 pubmed publisher |
| Zhu Y, Bian J, Lu D, To C, Lam C, Li K, et al. Alteration of EIF2 Signaling, Glycolysis, and Dopamine Secretion in Form-Deprived Myopia in Response to 1% Atropine Treatment: Evidence From Interactive iTRAQ-MS and SWATH-MS Proteomics Using a Guinea Pig Model. Front Pharmacol. 2022;13:814814 pubmed publisher |
| Liu X, Balaraman K, Lynch C, Hebron M, Wolf C, Moussa C. Novel Ubiquitin Specific Protease-13 Inhibitors Alleviate Neurodegenerative Pathology. Metabolites. 2021;11: pubmed publisher |
| Wang H, Qi W, Zou C, Xie Z, Zhang M, Naito M, et al. NEK1-mediated retromer trafficking promotes blood-brain barrier integrity by regulating glucose metabolism and RIPK1 activation. Nat Commun. 2021;12:4826 pubmed publisher |
| Fernandez Espejo E, Rodriguez de Fonseca F, Suarez J, Tolosa E, Vilas D, Aldecoa I, et al. Native α-Synuclein, 3-Nitrotyrosine Proteins, and Patterns of Nitro-α-Synuclein-Immunoreactive Inclusions in Saliva and Submandibulary Gland in Parkinson's Disease. Antioxidants (Basel). 2021;10: pubmed publisher |
| Brekk O, Honey J, Lee S, Hallett P, Isacson O. Cell type-specific lipid storage changes in Parkinson's disease patient brains are recapitulated by experimental glycolipid disturbance. Proc Natl Acad Sci U S A. 2020;117:27646-27654 pubmed publisher |
| Murakami H, Tokuda T, El Agnaf O, Ohmichi T, Miki A, Ohashi H, et al. Correlated levels of cerebrospinal fluid pathogenic proteins in drug-naïve Parkinson's disease. BMC Neurol. 2019;19:113 pubmed publisher |
| Uehara T, Choong C, Nakamori M, Hayakawa H, Nishiyama K, Kasahara Y, et al. Amido-bridged nucleic acid (AmNA)-modified antisense oligonucleotides targeting α-synuclein as a novel therapy for Parkinson's disease. Sci Rep. 2019;9:7567 pubmed publisher |
| Krejciova Z, Carlson G, Giles K, Prusiner S. Replication of multiple system atrophy prions in primary astrocyte cultures from transgenic mice expressing human α-synuclein. Acta Neuropathol Commun. 2019;7:81 pubmed publisher |
| Harischandra D, Rokad D, Neal M, Ghaisas S, Manne S, Sarkar S, et al. Manganese promotes the aggregation and prion-like cell-to-cell exosomal transmission of α-synuclein. Sci Signal. 2019;12: pubmed publisher |
| Li X, Koudstaal W, Fletcher L, Costa M, Van Winsen M, Siregar B, et al. Naturally occurring antibodies isolated from PD patients inhibit synuclein seeding in vitro and recognize Lewy pathology. Acta Neuropathol. 2019;137:825-836 pubmed publisher |
| Humphreys C, Jansen M, Muñoz Maniega S, González Castro V, Pernet C, Deary I, et al. A protocol for precise comparisons of small vessel disease lesions between ex vivo magnetic resonance imaging and histopathology. Int J Stroke. 2019;14:310-320 pubmed publisher |
| Henrich M, Geibl F, Lee B, Chiu W, Koprich J, Brotchie J, et al. A53T-α-synuclein overexpression in murine locus coeruleus induces Parkinson's disease-like pathology in neurons and glia. Acta Neuropathol Commun. 2018;6:39 pubmed publisher |
| Cai W, Feng D, Schwarzschild M, McLean P, Chen X. Bimolecular Fluorescence Complementation of Alpha-synuclein Demonstrates its Oligomerization with Dopaminergic Phenotype in Mice. EBioMedicine. 2018;29:13-22 pubmed publisher |
| Recasens A, Carballo Carbajal I, Parent A, Bove J, Gelpi E, Tolosa E, et al. Lack of pathogenic potential of peripheral ?-synuclein aggregates from Parkinson's disease patients. Acta Neuropathol Commun. 2018;6:8 pubmed publisher |
| Zunke F, Moise A, Belur N, Gelyana E, Stojkovska I, Dzaferbegovic H, et al. Reversible Conformational Conversion of α-Synuclein into Toxic Assemblies by Glucosylceramide. Neuron. 2018;97:92-107.e10 pubmed publisher |
| Rockenstein E, Ostroff G, Dikengil F, Rus F, Mante M, Florio J, et al. Combined Active Humoral and Cellular Immunization Approaches for the Treatment of Synucleinopathies. J Neurosci. 2018;38:1000-1014 pubmed publisher |
| Fischer D, Manfredsson F, Kemp C, Cole Strauss A, Lipton J, Duffy M, et al. Subthalamic Nucleus Deep Brain Stimulation Does Not Modify the Functional Deficits or Axonopathy Induced by Nigrostriatal α-Synuclein Overexpression. Sci Rep. 2017;7:16356 pubmed publisher |
| Xu C, Kang W, Chen Y, Jiang T, Zhang J, Zhang L, et al. DJ-1 Inhibits ?-Synuclein Aggregation by Regulating Chaperone-Mediated Autophagy. Front Aging Neurosci. 2017;9:308 pubmed publisher |
| Spencer B, Valera E, Rockenstein E, OVERK C, Mante M, Adame A, et al. Anti-α-synuclein immunotherapy reduces α-synuclein propagation in the axon and degeneration in a combined viral vector and transgenic model of synucleinopathy. Acta Neuropathol Commun. 2017;5:7 pubmed publisher |
